In light of these findings, the National Comprehensive Cancer Network (NCCN) has underscored the importance of evaluating MGMT promoter methylation status as a critical component of the molecular diagnostic workup for all high-grade gliomas, encompassing both grade 3 and grade 4 tumors. Here, MGMT is linked to central nervous system cancer.